View ValuationTempus AI 향후 성장Future 기준 점검 1/6Tempus AI (는) 각각 연간 47.5% 및 16.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 48.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 19.1% 로 예상됩니다.핵심 정보47.5%이익 성장률48.28%EPS 성장률Life Sciences 이익 성장0%매출 성장률16.4%향후 자기자본이익률19.06%애널리스트 커버리지Good마지막 업데이트19 May 2026최근 향후 성장 업데이트공시 • May 07Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2026Tempus AI, Inc. increased earnings guidance for the full year 2026. For the period, the company expects revenue in range of $1.59 billion to $1.60 billion, which represents ~25% annual growth.Breakeven Date Change • Dec 31Forecast to breakeven in 2028The 14 analysts covering Tempus AI expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$17.7m in 2028. Average annual earnings growth of 44% is required to achieve expected profit on schedule.공시 • Aug 08Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2025Tempus AI, Inc. increased earnings guidance for the full year 2025. For the period, the company now expects revenue of approximately $1.26 billion for the consolidated business, which represents approximately 82% annual growth.공시 • May 07Tempus AI, Inc. Increases Earnings Guidance for Full Year 2025Tempus AI, Inc. increased earnings guidance for full year 2025. The company now expects full year revenue of approximately $1.25 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 80% annual growth.공시 • Feb 25Tempus Ai, Inc. Provides Earnings Guidance for Full Year 2025Tempus AI, Inc. provided earnings guidance for full year 2025. Tempus now expects full year 2025 revenue of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth.모든 업데이트 보기Recent updates공시 • May 07Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2026Tempus AI, Inc. increased earnings guidance for the full year 2026. For the period, the company expects revenue in range of $1.59 billion to $1.60 billion, which represents ~25% annual growth.Reported Earnings • May 06First quarter 2026 earnings released: US$0.70 loss per share (vs US$0.40 loss in 1Q 2025)First quarter 2026 results: US$0.70 loss per share (further deteriorated from US$0.40 loss in 1Q 2025). Revenue: US$348.1m (up 36% from 1Q 2025). Net loss: US$125.9m (loss widened 85% from 1Q 2025). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Global Life Sciences industry.공시 • Apr 21Tempus AI, Inc. to Report Q1, 2026 Results on May 05, 2026Tempus AI, Inc. announced that they will report Q1, 2026 results on May 05, 2026공시 • Apr 14Tempus AI, Inc. Launches Automated Active Follow-Up ServiceTempus AI, Inc. announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an active follow-up track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus’ secure, AI-enabled physician portal. Because NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient’s ongoing treatment journey. Tempus is addressing this challenge by automatically surfacing updated therapy recommendations when clinical guidelines change or new therapeutic options emerge—all without requiring a new patient sample. This ensures that patient insights remain as current as the science, supporting evidence-based decision-making throughout the patient’s treatment journey.공시 • Apr 08Tempus AI, Inc., Annual General Meeting, May 21, 2026Tempus AI, Inc., Annual General Meeting, May 21, 2026.공시 • Apr 01Tempus AI, Inc. Announces Results from ALERT TrialTempus AI, Inc. announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electronic clinician notifications (ECNs) integrated into the electronic health record (EHR) significantly improve the timely evaluation and treatment of patients with significant aortic stenosis (AS) and mitral regurgitation (MR). Valvular heart disease is a leading cause of morbidity and mortality, yet it remains frequently undertreated. For patients with untreated symptomatic severe AS, mortality approaches 50% within just two years. Similarly, untreated severe MR carries a median survival of only five years. The ALERT trial was designed to determine if automated, AI-driven alerts could bridge this critical gap in care delivery. By leveraging the Tempus Next platform, which applies natural language processing to accurately extract findings from echocardiogram reports, the trial enabled real-time detection of significant disease and automatically delivered notifications with site-specific guideline-based care notifications directly to providers. The ALERT trial included 765 clinicians and 2,016 echocardiograms across five U.S. health systems and 35 hospitals. The study met its primary endpoint, demonstrating that automated ECN alerts were superior to usual care in a win ratio analysis (win ratio 1.27; P = .007), meaning patients in the alert group were 27% more likely to be evaluated by the multidisciplinary heart team or receive a valve intervention than those in the usual care group. By delivering actionable data directly to providers, the system facilitated a 40% relative increase in life-saving valve procedures (13.4% vs. 9.6%) and a 27% increase in multidisciplinary heart team evaluations (22.7% vs. 17.9%) within just 90 days. These alerts effectively reduced clinical inertia, prompting earlier specialist referrals and ensuring patients received interventions within established benchmarks for timely care. Beyond clinical efficiency, a central objective of the ALERT trial was to confront the persistent disparities that leave women, older adults, racial and ethnic minorities, and rural residents at higher risk of being undertreated. These findings suggest that EHR-integrated clinical decision support can serve as a powerful, scalable 'safety net,' standardizing care delivery to help ensure high-risk findings receive timely action regardless of a patient's demographics or care setting. While the ALERT trial was conducted in collaboration with Medtronic, the automated clinician notifications were designed to be device-agnostic to promote standardized care delivery, without requiring providers to use specific Medtronic devices for recommended evaluations or interventions.공시 • Mar 11Tempus Ai, Inc. Announces the Publication of A New Study in Jco Precision OncologyTempus AI, Inc. announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex identify actionable findings that are missed by more limited standard in-network testing. While organizations like ASCO and the NCCN strongly advocate for CGP to guide precision therapies, current guidelines often lack specificity regarding the exact composition or essential features required within these panels. This research demonstrates that CGP value extends far beyond simple panel size, highlighting the utility of advanced testing features to more fully capture clinically relevant findings. In the study, 12% (approximately 1 in 8) of patients across the pilot and expanded cohorts had potentially actionable findings associated with an approved therapy identified solely through advanced Tempus features—such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing—that would otherwise have been missed by less comprehensive tests.Recent Insider Transactions • Feb 26Executive VP recently sold Mex$20m worth of stockOn the 20th of February, Andrew Polovin sold around 19k shares on-market at roughly Mex$1,026 per share. This transaction amounted to 58% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$353m more than they bought in the last 12 months.Reported Earnings • Feb 25Full year 2025 earnings released: US$1.41 loss per share (vs US$6.23 loss in FY 2024)Full year 2025 results: US$1.41 loss per share (improved from US$6.23 loss in FY 2024). Revenue: US$1.27b (up 83% from FY 2024). Net loss: US$245.0m (loss narrowed 67% from FY 2024). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Global Life Sciences industry.공시 • Feb 25+ 1 more updateTempus AI, Inc. (NasdaqGS:TEM) acquired Oneome LLC.Tempus AI, Inc. (NasdaqGS:TEM) acquired Oneome LLC in November 2025. Tempus AI, Inc. (NasdaqGS:TEM) completed the acquisition of Oneome LLC in November 2025.공시 • Feb 18Tempus AI, Inc. Announces Novel Pan-Cancer HRD-RNA AlgorithmTempus AI, Inc. announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays. Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. Unlike traditional DNA tests that analyze static "genomic scars"--which may persist even after a patient develops drug resistance--this RNA-based approach provides a dynamic, real-time assessment of a tumor's functional status. By analyzing gene expression rather than structural DNA damage, the algorithm can detect HRD in patients and cancer types where genomic scarring is rare or difficult to identify. This advanced methodology allows the model to capture HRD status in patients who might be missed by DNA-based assays, significantly expanding the population that can be identified for potentially life-saving therapies. A real-world validation study demonstrates that HRD-RNA positive metastatic pancreatic patients treated with first line platinum-based regimens showed a significant reduction in mortality risk compared to those receiving non-platinum first line therapies. These findings, including the complete supporting data, will be published later this year. HRD-RNA is currently available for research use only in the detection of HRD status within solid tumor patient populations and for the identification of patients likely to respond to platinum regimens or PARP inhibitor therapy. Clinical availability is expected later this year.공시 • Feb 10Tempus AI, Inc. to Report Q4, 2025 Results on Feb 24, 2026Tempus AI, Inc. announced that they will report Q4, 2025 results on Feb 24, 2026공시 • Jan 27Tempus Ai, Inc. Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional BiomarkersTempus AI, Inc. announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), and PD-L1. IPS is a multimodal biomarker that combines known and novel clinical and immune-related biomarkers from DNA and RNA analysis to predict a patient's response to ICI-based therapy. The new clinical validation results demonstrate that IPS consistently outperforms conventional biomarkers, highlighting its potential to change the way physicians can identify patients most likely to benefit from immunotherapy. In four independent validation cohorts of pan-cancer metastatic solid organ cancer patients, IPS was shown to be a more accurate predictor of ICI outcomes (HR=0.45) than TMB, MSS, and PD-L1, demonstrating prognostic utility that is independent of those conventional biomarkers. IPS identified 13% of patients with microsatellite stable colorectal cancer who demonstrated strong real-world overall survival with ICI treatment (HR=0.2), indicating that ICI immunotherapy may be a viable option for a key patient population that might have been overlooked with conventional biomarkers alone. Beyond colorectal cancer, the study's findings highlight how IPS could expand treatment options for patients with rare cancers. IPS classified 17% of patients with rare metastatic solid tumors as "IPS-High," despite these patients not falling within a cancer-specific FDA-approved ICI label. The significant difference in median real-world overall survival in "IPS High" versus "IPS-Low" patients (HR=0.26) shows that ICI could be a relevant and potentially life-saving option for patients that might otherwise be missed. The test is available as an add-on for clinicians ordering Tempus' xT (DNA) and xR (RNA) assays, helping to manage patients on immunotherapy by utilizing data already collected as part of a patient's standard sequencing.공시 • Jan 21Tempus AI, Inc. Announces the Launch of Paige PredictTempus AI, Inc. announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence or absence of clinically actionable and relevant biomarkers directly from a single H&E slide, offering physicians insights even when tissue samples are insufficient for full molecular profiling. As the demand for next-generation sequencing (NGS) and immunohistochemistry (IHC) testing grows, so does the challenge of limited tissue availability. When a sample is "quantity not sufficient" (QNS), patients can face delays of days or weeks for testing results, waiting for repeat biopsies or alternative testing, ultimately prolonged uncertainty and potentially impacting treatment options. Paige Predict's ability to use an H&E image to identify biomarkers that are more or less likely to be present in the specimen can be used by clinicians to inform the sequence in which they will order confirmatory tissue-based tests, maximizing the likelihood of receiving an actionable result before exhausting tissue. Leveraging Tempus and Paige's intelligent digital pathology platform and proprietary AI products, Paige Predict identifies critical biomarker information from even scarce amounts of tissue and analyzes H&E images to predict the likelihood of 123 biomarkers and oncogenic molecular pathways in 16 cancer types, including NSCLC, prostate, breast, pancreatic, colorectal, and more. Results are automatically delivered with the clinical report to ordering physicians. Paige Predict was built using Paige's foundation model and a combined, multimodal cohort from Tempus and Paige, which contains de-identified data on over 200,000 patients. The model has been rigorously validated to demonstrate performance, generalizability and robustness across multiple, diverse datasets, including a large-scale cohort from Tempus.Breakeven Date Change • Dec 31Forecast to breakeven in 2028The 14 analysts covering Tempus AI expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$17.7m in 2028. Average annual earnings growth of 44% is required to achieve expected profit on schedule.Recent Insider Transactions • Dec 14Independent Director recently sold Mex$5.2m worth of stockOn the 5th of December, Wayne Frederick sold around 4k shares on-market at roughly Mex$1,405 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth Mex$166m. Insiders have been net sellers, collectively disposing of Mex$5.4b more than they bought in the last 12 months.Recent Insider Transactions • Dec 10Independent Director recently sold Mex$5.2m worth of stockOn the 5th of December, Wayne Frederick sold around 4k shares on-market at roughly Mex$1,405 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth Mex$166m. Insiders have been net sellers, collectively disposing of Mex$7.3b more than they bought in the last 12 months.공시 • Dec 09Tempus AI, Inc. Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer SymposiumTempus AI, Inc. announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9-12 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Tempus will highlight its latest scientific and clinical research findings via ten poster presentations: Integrative Modeling of Multimodal Real-World Data for Improved Risk Stratification of First-Line CDK4/6 inhibitor plus endocrine treatment and identify predictors of response. This study demonstrated that multimodal real-world data collected during routine care can provide valuable insights into the biology of response to CDK4/6 inhibitors in patients with metastatic breast cancer and help improve patient stratification. Distinct Transcriptional and Immunosuppressive Microenvironment Signatures in PIK3CA-mutant Hormone Receptor Positive (HR+)/HER2- Metastatic Breast Cancer (MBC). Date/Time: December 10, 2025, 12:30 p.m. - 2:30 p.m. CDT. Presentation Number: PS1-11-08. Summary: This study compared transcriptomic and immune profiles in HR+/HER2- metastatic breast cancer across wild-type, PIK3CA-mutants, ESR1-mutant, and co-mutant groups. SFRP2 downregulation was specific to ESR1-mutant tumors, while SCGB2A2 was robustly upregulated in PIK3CA- mutant and co-mutant tumors, suggesting its potential as a diagnostic and therapeutic target. Immune analysis revealed increased M2 macrophages and regulatory T cells in PIK3CA- mutualant and co-mutant tumor, with the most pronounced immunosuppressive microenvironment in PIK3CA-Mutant cases. A notable percentage of patients with localized and de novo metastatic disease displayed TMB high status and/or PD-L1 positivity. Additionally, TMB-high and PD-L1 positive patients with de novo metastatic disease treated with first-line chemotherapy or anti-HER2 therapy had significantly worse real-world overall survival (rwOS), suggesting a potential therapeutic benefit of incorporating immunotherapy into the treatment paradigm, in both localized and metastatic disease settings. Furthermore, observed ethnic HLA polymorphisms in the cohort may contribute to differences in outcomes and could potentially guide the development of population-specific immunotherapeutic strategies. Real-World Data (RWD) Outcome Analysis of ESR1 Mutation Emergence in HR+/HER2 - Metastatic Breast Cancer through the Continuum of Standard of Care Hormonal Therapy. Date/Time: Friday, December 12, 2025, 12:30p.m. - 2:00 p.m. CDT, Presentation Number: PS5-05-02. Summary: This large multimodal RWD outcome analysis from longitudinal molecular surveillance testing (xF) in HR+/HER2. mBC patients treated with AI+CDK4/6 inhibitor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer. Date/Time: December 12, 2025, 12; 12:30 p.m., 2:00 p.m., CDT and Presentation Number: PS5.05-02; Summary: This large multimodAL RWD outcome analysis from longitudinal Molecular surveillance testing (xF)in HR+/HER2- mBC pts treated with AI+ CDK4/6 inhibitors treated with AI+CDK 4/6 inhibitor plus end endocrine treatment and resistance. These insights are essential for pinpointing patient populations who may benefit from novel therapies and for optimizing treatment strategies to ultimately improve outcomes for those with advanced disease.Recent Insider Transactions • Nov 23Co-Founder recently sold Mex$166m worth of stockOn the 20th of November, Eric Lefkofsky sold around 130k shares on-market at roughly Mex$1,275 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Eric has been a net seller over the last 12 months, reducing personal holdings by Mex$4.4b.New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$204m Forecast net loss in 3 years: US$18m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Significant insider selling over the past 3 months (Mex$103m sold).Reported Earnings • Nov 06Third quarter 2025 earnings released: US$0.46 loss per share (vs US$0.46 loss in 3Q 2024)Third quarter 2025 results: US$0.46 loss per share. Revenue: US$334.2m (up 85% from 3Q 2024). Net loss: US$80.0m (loss widened 5.5% from 3Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Global Life Sciences industry.공시 • Nov 05+ 1 more updateTempus AI, Inc. Announces Six Abstracts Accepted for Presentation At the Society for Immunotherapy of Cancer Annual Meeting 2025Tempus AI, Inc. announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. This year, Tempus will highlight its latest scientific and clinical research findings via six poster presentations. A novel multi-omic algorithm to predict real-world outcomes among patients with rare, advanced, solid cancers treated with off-label immune checkpoint inhibitors. Date/Time: November 7, 5:10-6:35 p.m. ET. Location: Exhibit Halls AB. Presentation Number: 157. This study investigates the utility of the Immune Profile Score (IPS) as a molecular signature to predict the effectiveness of immune checkpoint inhibitor (ICI) therapy in rare, advanced solid cancers. Given the clinical unmet need for rare, heterogeneous cancers, the study evaluated 90 eligible patients from Tempus' de-identified real-world database who had a rare, advanced solid cancer diagnosis and received off-label ICI treatment, excluding those with high TMB or MSI. Patients were further categorized as IPS-high or IPS-low. The findings demonstrated that IPS-high patients experienced significantly longer overall survival compared to those categorized as IPS-low. Importantly, IPS maintained its prognostic significance across all patient subgroups and clinically relevant confounders. These results support IPS as a pan-cancer biomarker capable of accurately stratifying ICI treatment outcomes and potentially supporting the label expansion of ICIs to various rare cancer types. Furthermore, a comparison of IPS risk stratification on ICI therapy versus prior non-ICI regimen provided additional insight about IPS's utility as an ICI-specific biomarker. This hypothesis-generating data address an unmet need for patients whom an ICI therapy and predictive biomarker are urgently needed. Ultrahigh tumor mutational burden (TMB) is associated with improved survival outcomes in patients (Pts) treated with immune checkpoint inhibitors (ICIs). Date/Time: Saturday, November 8, 2025; 5:10-6: 35 p.m. ET; Location: Exhibit Halls AB; Presentation Number: 136; Summary: This research evaluates the prognostic value of defining an "ultrahigh" tumor mutational burden (T MB) threshold (40 mutations/MB) compared to the standard 10 mt/MB cutoff for patients receiving immune checkpoint inhibitor (ICI") therapy. Using Tempus Lens, the research team defined a cohort of 17,449 patients with five different cancer types (melanoma, lung, GI, non-melanoma skin, and uterine) from Tempus' de- identified multimodal database. The analysis sought to compare real-world objective response rates (rwORR) and overall survival (rwOS) across low, high, and ultrahigh TMB groups. The findings indicate that patients in the ultrahigh TMB group experience significantly improved clinical outcomes, including enhanced rwORR and better rwOS. This ultrahigh TMB status is also linked to a distinct tumor microenvironment, specifically showing a higher degree of regulatory T cell and myeloid cell infiltration, suggesting that ultrahigh TMB may serve as a novel marker for predicting ICI responsiveness. Impact of androgen receptor mutations on immune infiltration in castration resistant prostate cancer. Date/Time: Saturday, Nov. 8; 5:10-6-6:35 p. m. ET; Location: Exhibit Hall AB; Presentation Number: 140; Summary: A detailed analysis using Tempus' de-identified Real-world database examined the relationship between androgen receptor (AR) alterations and the immune microenvironment in 1,556 patients with off-label immune micro environment in 1,556 patients with the immune micro environment in 1,58 patients with the immune microenvironment.공시 • Oct 21Tempus AI, Inc. to Report Q3, 2025 Results on Nov 04, 2025Tempus AI, Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025공시 • Sep 23Tempus AI, Inc. Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS in Vitro Diagnostic DeviceTempus AI, Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life science tool to support drug development programs. RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases, including enhanced fusion detection. RNA analysis is increasingly an important tool in research and development because it can identify molecular pathways and networks that are directly involved in disease progression. The Tempus xR IVD assay is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of rearrangements in two genes, using RNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens from patients with solid malignant neoplasms. Information provided by xR IVD is intended to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed malignant neoplasms. Results from xR IVD are not intended to be prescriptive or conclusive for labeled use of any specific therapeutic product. The FDA authorization further solidifies Tempus as a one-stop-shop for precision medicine solutions. Collaborators can leverage Tempus' comprehensive collection of intelligent diagnostics and growing multimodal data that supports therapeutic innovation. xR IVD is one of the many solutions Tempus is applying to advance oncology therapeutic research and development.공시 • Sep 11Tempus AI, Inc. Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel DeviceTempus AI, Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device's capabilities for cardiac MR image analysis. Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization. AI-enabled radiology, like Tempus Pixel, enhances medical imaging by rapidly analyzing scans, highlighting subtle abnormalities, and generating consistent, actionable insights. By improving accuracy and efficiency, it empowers clinicians to make faster, more informed decisions and deliver personalized patient care. Unlike conventional MR images that show only brightness differences, T1 and T2 maps provide precise numerical values to cardiac tissue characteristics, helping clinicians detect conditions such as fibrosis, inflammation, or edema, that may otherwise go undetected. With its newly cleared functionality, Tempus Pixel can now generate T1 and T2 inline map directly from raw MRI data, even when the scanner itself does not produce them, calculating values at every pixel across the image to create detailed DICOM maps for comprehensive tissue assessment. Tempus has developed and deployed a suite of advanced algorithms across radiology and pathology, helping physicians deliver more precision, personalized care. Its strategic acquisitions have further strengthened its footprint in these fields. In 2022, Tempus acquired Arterys, incorporating its AI-powered tools for analyzing imaging data--ranging from lung CT scans and chest X-rays to cardiac MRIs-- into Tempus' platform. Most recently, Tempus acquired Paige, an AI company specializing in digital pathology, bringing a proprietary dataset of almost 7 million clinically annotated, de-identified pathology slides to accelerate Tempus' efforts.공시 • Sep 09Tempus AI, Inc. Announces New Study in JCO Precision Oncology Validating PurIST Algorithm for Enhanced Therapy Selection in Pancreatic CancerTempus AI, Inc. announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company's PurIST®? algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of PurIST into routine clinical care for patients with advanced PDAC, with the aim of informing first-line chemotherapy selection and improving patient outcomes. Pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and a five-year survival rate of just 12%. For patients with advanced, unresectable PDAC, the two most common first-line chemotherapy regimens, FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP), have shown variable efficacy, and clinicians have lacked robust biomarkers to guide optimal therapy selection. To address this challenge, Tempus collaborated with GeneCentric to develop and deploy PurIST, a clinically validated, RNA-based algorithm test that classifies PDAC tumors as either "classical" or "basal" subtypes. The Tempus-led study analyzed a real-world cohort of 931 patients with advanced PDAC, using the Tempus xR RNA sequencing platform to assign PurIST subtypes. Patients were treated with either first-line FFX or GnP, and clinical outcomes were assessed according to PurIST classification. The study's findings establish PurIST as both a prognostic and predictive biomarker, enabling clinicians to personalize first-line therapy for advanced PDAC patients and maximize the likelihood of improved survival. Prognostic Value: Among patients treated with FFX (N=536), those with the classical subtype had a significantly longer median overall survival (OS) of 11.8 months, compared to 7.0 months for basal subtype patients (Hazard Ratio [HR]=1.86; p; Predictive Value: In patients with the classical subtype and good performance status (ECOG 0 or 1, N=311), treatment with FFX was associated with a 33% relative risk reduction in death compared to GnP (HR=0.67; p<0.009). No comparable benefit was observed in basal subtype patients.Recent Insider Transactions • Aug 30Independent Director recently sold Mex$28m worth of stockOn the 26th of August, Theodore Leonsis sold around 20k shares on-market at roughly Mex$1,418 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth Mex$57m. Insiders have been net sellers, collectively disposing of Mex$7.1b more than they bought in the last 12 months.공시 • Aug 23Tempus AI, Inc. (NasdaqGS:TEM) acquired Paige.AI, Inc. in a transaction valued at $81.2 million.Tempus AI, Inc. (NasdaqGS:TEM) acquired Paige.AI, Inc. in a transaction valued at $81.2 million on August 22, 2025. The consideration consists of $81.25 million, which is being paid predominantly in Tempus common stock, as well as Tempus’ assumption of Paige’s remaining commitment under its existing Microsoft Azure cloud services agreement. Morgan Stanley (NYSE:MS) acted as financial advisor to Paige.AI, Inc. Tempus AI, Inc. (NasdaqGS:TEM) completed the acquisition of Paige.AI, Inc. on August 22, 2025.Recent Insider Transactions • Aug 17Independent Director recently sold Mex$57m worth of stockOn the 13th of August, Theodore Leonsis sold around 44k shares on-market at roughly Mex$1,302 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$7.0b more than they bought in the last 12 months.Reported Earnings • Aug 10Second quarter 2025 earnings released: US$0.25 loss per share (vs US$6.86 loss in 2Q 2024)Second quarter 2025 results: US$0.25 loss per share (improved from US$6.86 loss in 2Q 2024). Revenue: US$314.6m (up 90% from 2Q 2024). Net loss: US$42.8m (loss narrowed 92% from 2Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry.공시 • Aug 09Tempus AI, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.Tempus AI, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Class A Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Aug 08Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2025Tempus AI, Inc. increased earnings guidance for the full year 2025. For the period, the company now expects revenue of approximately $1.26 billion for the consolidated business, which represents approximately 82% annual growth.공시 • Aug 02Bragar Eagel & Squire, P.C. Files A Class Action Lawsuit Against Tempus Ai, IncBragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of "round-tripping" capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable "pass-through payment" via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025.공시 • Jul 22Tempus AI, Inc. to Report Q2, 2025 Results on Aug 08, 2025Tempus AI, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025공시 • Jun 03+ 1 more updateTempus AI, Inc. Introduces xM, an Assay to Monitor Immunotherapy Response for Patients with Advanced CancersTempus AI, Inc. announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It is currently available for research use only, with clinical availability expected later this year. In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding estimated response rate of 20.13%.1 xM for TRM is designed to quantify changes in circulating tumor DNA (ctDNA) longitudinally from a blood sample, enabling early molecular response assessment in patients with advanced cancers receiving immunocheckpoint inhibitors (ICI) alone or combination therapies. xM for TRM leverages a unique multi-parametric algorithm, integrating copy number variations (CNVs), along with somatic andgerline variant allele frequencies (VAFs), for a comprehensive and robust estimation of circulating tumor fraction. Tempus is presenting new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®?) Annual Meeting, highlighting the assay's potential to help clinicians monitor response and refine treatment strategies for patients with advanced cancers. Title: A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors. Date/Time: June 2, 2025; 1:30 PM-4:30 PM CDT; Location: Poster Section Developmental Therapeutics--Immunotherapy (Poster #205). Overview: Tempus xM for TRM, a liquid biopsy test, monitors treatment response by tracking ctDNA dynamics over time. Longitudinal non-molecular responders are associated with worse survival compared to molecular responders, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions.공시 • Jun 01Tempus Ai, Inc. Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using Its Novel Foundation ModelTempus AI, Inc. announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality. Over the past decade, Tempus has built a multimodal data library of over 40 million research records, including more than 1.5 million records with matched clinical data linked with genomic information, 2 million records with imaging data, and approximately 300,000 records with genomic and whole transcriptomic data. The scale and size of this data library will allow the company to uncover groundbreaking discoveries that were previously out of reach. Fuses will accelerate Tempus' comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. Insights from Fuses will be developed into clinically validated algorithmic diagnostics that may enable highly personalized care, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. Tempus has already begun this work with last year's launch of its Immune Profile Score (IPS) a multimodal biomarker that can be used as a prognostic indicator for adult patients with metastatic pan-solid tumors eligible for immune checkpoint inhibitor (ICI)-based therapy. The foundational model behind Fuses is learning generalizable rules determining prognosis and drug benefit in real-world practice. With the goal of furthering researchers' understanding of why certain clinical trials fail, identify new indications for investigational drugs, optimize trial design, and uncover combination therapies to broaden patient benefit. By revealing biomarker rules, the model may also surface mechanisms of drug response and resistance to inspire a new generation of companion diagnostics and therapeutic research.Recent Insider Transactions • May 24Co-Founder recently sold Mex$20m worth of stockOn the 20th of May, Eric Lefkofsky sold around 17k shares on-market at roughly Mex$1,218 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth Mex$1.7b. Eric has been a net seller over the last 12 months, reducing personal holdings by Mex$4.2b.Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Director Jennifer Doudna was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 07First quarter 2025 earnings released: US$0.40 loss per share (vs US$1.47 loss in 1Q 2024)First quarter 2025 results: US$0.40 loss per share (improved from US$1.47 loss in 1Q 2024). Revenue: US$255.7m (up 75% from 1Q 2024). Net loss: US$68.0m (loss narrowed 27% from 1Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Global Life Sciences industry.공시 • May 07Tempus AI, Inc. Increases Earnings Guidance for Full Year 2025Tempus AI, Inc. increased earnings guidance for full year 2025. The company now expects full year revenue of approximately $1.25 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 80% annual growth.공시 • May 06Tempus Ai, Inc. Announces Notetaker, Its Ai-Powered Clinical Assistant for PsychiatryTempus AI, Inc. has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, aggressively records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records. Notetaker complements Tempus' existing mental health platform designed to support clinicians in delivering personalized care. It joins other precision medicine solutions, including the Tempus nP pharmacogenomic test and PRO, the company's patient reported outcome solution. Key features of Notetaker include: Recording Sessions: Notetaker effortlessly transcribes and processes the session in real-time, capturing key details with precision, including specialized psychiatric terminology and medications. Generating Notes: At the end of each session, a clinical note is automatically created, highlighting essential information such as symptoms, progress, and action plans for quick review. Refining During Review: Clinicians can easily review and modify the autogenerated note using the Magic Edit features to adjust formatting or details according to their preferences. Care Gap Notification: Notetaker identifies and helps close care gaps with real-time pharmacogenomic insights for medications under consideration. Notetaker is capable of understanding more than 30 languages, including English, Spanish, and Chinese. It can seamlessly recognize language switching without the need to set a specific language in advance. With adjustable settings tailored for telehealth, in-person sessions, and dictation, Notetaker adapts to various environments for adequate audio capture. While providers are responsible for obtaining all necessary consents before recording sessions, Notetaker supports HIPAA-compliant data transfer and storage.공시 • May 01Tempus AI, Inc. Time Network Expands Support of Phase I Clinical Trials to Accelerate Activation and EnrollmentTempus AI, Inc. is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform with a focus on activating and enrolling quickly across over 40 phase I-capable research centers. Most recently, TIME enrolled the First Patient In (FPI) for multiple phase I trials. The TIME Network is powered to efficiently enroll patients within its participating data-integrated site base, in which patients are identified and matched to trials and sites are activated within days or weeks. At the Taylor Cancer Research Center (TCRC), Tempus activated the site in approximately two weeks for the Nimbus 9216-101 study, and enrolled its first patient within one month of site activation. For the Pathos P300-02-001 study, Tempus screened and enrolled the trial's first and second patients at Nebraska Cancer Specialists and Oncology Consultants within weeks.공시 • Apr 28Tempus AI, Inc. Introduces Loop, an AI-Powered Target Discovery and Validation PlatformTempus AI, Inc. announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic development. One of the biggest industry challenges has been translating promising preclinical experiments into treatments that can benefit patients. Conventional approaches in target discovery and validation rely on cell lines or animal models, which may not be reliable representations of human tumors. Loop's approach is uniquely powerful because it leverages Tempus' rich RWD to identify patient subpopulations with similar clinical, pathologic, and molecular patterns, followed by use of systems biological approaches to help reveal novel target genes and multimodal signatures. These signatures allow Tempus to seamlessly map patient subcohorts to relevant patient-derived organoids (PDOs), which the company has been expanding for years. By ensuring continuity between RWD and PDOs, Tempus can validate targets using high-throughput functional screens in models that more closely reflect patient attributes. This seamless integration--RWD to PDO and back--can help to enable rapidhesis generation and testing in the most relevant disease models, accelerating target discovery and validation. Tempus has already deployed its Loop platform to prioritize drug targets in patient subpopulations with severe unmet needs for a large pharmaceutical company. By incorporating a lab-in-the-loop strategy, its biological modeling and functional screening capabilities were able to confirm and validate these targets within a year, a significant acceleration of the standard discovery timeline.공시 • Apr 24Tempus AI, Inc. to Report Q1, 2025 Results on May 06, 2025Tempus AI, Inc. announced that they will report Q1, 2025 results on May 06, 2025공시 • Apr 01Tempus AI, Inc., Annual General Meeting, May 20, 2025Tempus AI, Inc., Annual General Meeting, May 20, 2025.공시 • Mar 12Tempus AI, Inc. (NasdaqGS:TEM) acquired Deep 6 AI Inc.Tempus AI, Inc. (NasdaqGS:TEM) acquired Deep 6 AI Inc. on March 11, 2025. Tempus AI, Inc. (NasdaqGS:TEM) completed the acquisition of Deep 6 AI Inc. on March 11, 2025.공시 • Feb 25Tempus Ai, Inc. Provides Earnings Guidance for Full Year 2025Tempus AI, Inc. provided earnings guidance for full year 2025. Tempus now expects full year 2025 revenue of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth.Reported Earnings • Feb 25Full year 2024 earnings released: US$6.23 loss per share (vs US$4.20 loss in FY 2023)Full year 2024 results: US$6.23 loss per share (further deteriorated from US$4.20 loss in FY 2023). Revenue: US$693.4m (up 30% from FY 2023). Net loss: US$746.3m (loss widened 181% from FY 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry.공시 • Feb 11Tempus AI, Inc. to Report Q4, 2024 Results on Feb 24, 2025Tempus AI, Inc. announced that they will report Q4, 2024 results on Feb 24, 2025공시 • Feb 04Tempus AI, Inc (NasdaqGS:TEM) completed the acquisition of Ambry Genetics Corporation from REALM IDx, Inc.Tempus AI, Inc (NasdaqGS:TEM) agreed to acquire Ambry Genetics Corporation from REALM IDx, Inc. for approximately $600 million on November 4, 2024. Pursuant to the terms of the Purchase Agreement, consideration for the Acquisition consists of $375 million in cash, subject to adjustment for cash, unpaid indebtedness, unpaid transaction expenses and net working capital of Ambry, plus the issuance of an aggregate of 4,843,136 shares of the Tempus AI, Inc’s Class A common stock. In connection with the Purchase Agreement, Tempus AI, Inc entered into a debt commitment letter, dated November 4, 2024, with affiliates of Ares Capital Corporation, pursuant to which Ares has committed to provide (i) a $100 million senior secured revolving credit facility and (ii) additional term loans in an aggregate principal amount of $200 million. The Company expects to utilize borrowings under the Additional Term Loan and the Revolving Credit Facility to fund the Cash Consideration for the Acquisition and to pay fees and expenses related thereto. The consummation of the Acquisition is subject to certain specified closing conditions set forth in the Purchase Agreement, including the receipt of certain regulatory approvals. Subject to the terms of the Purchase Agreement, Tempus AI, Inc is required to use reasonable best efforts to obtain the approval required pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. For the period ending March 31, 2024, Ambry Genetics Corporation reported total revenue of $240 million, operating loss of $8 million, reported total assets of $160 million and Consolidated net assets of $101 million. The expected completion of the transaction in first quarter of 2025. Cowen Inc. acted as financial advisor for Tempus AI, Inc. Richard Ginsberg and Erin Kirchner of Cooley LLP acted as legal advisor to Tempus AI, Inc. Andrew L. Bab of Debevoise & Plimpton LLP and Yasuhiro Kasahara of Nagashima Ohno & Tsunematsu acted as legal advisors to REALM IDx, Inc. TD Securities Inc. acted as a financial advisor to Tempus AI, Inc. Mitsubishi UFJ Morgan Stanley Securities acted as the financial advisor to Konica Minolta. Tempus AI, Inc (NasdaqGS:TEM) completed the acquisition of Ambry Genetics Corporation from REALM IDx, Inc. on February 03, 2025.Recent Insider Transactions • Jan 26Co-Founder recently sold Mex$1.3b worth of stockOn the 24th of January, Eric Lefkofsky sold around 1m shares on-market at roughly Mex$1,039 per share. This transaction amounted to 3.5% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth Mex$1.6b. This was Eric's only on-market trade for the last 12 months.공시 • Jan 21Tempus AI, Inc. Announces National Launch of olivia, its AI-Enabled Personal Health Concierge App for PatientsTempus AI Inc. announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. olivia is designed to address two core objectives - centralizing patients' health data and making that data accessible and actionable through AI. The app enables patients to bring their health information into one unified platform. Patients can connect directly to over 1,000 health systems through electronic health record (EHR) integration, sync data from health devices to track daily metrics, or manually upload health records. olivia then organizes that data into a dynamic timeline where patients can access their records, including lab results, imaging reports, visit summaries, and even deep clinical data such as DICOM images, which can be shared directly with a patient's care team. olivia's AI-enabled capabilities allow patients to ask questions about their records, summarize their health information, and receive responses informed by their data; for instance, patients can query, "summarize my health status," and olivia will provide a clear, concise summary of information in health data. Additionally, olivia connects to external resources, such as clinicaltrials.gov, to supplement the personalized insights offered from existing health data. A few, new features of olivia include: Smart Profile Summary: olivia synthesizes a patient's data - from both their provider and their manual profiles - into an AI-generated smart profile, detailing information such as their clinical diagnoses, family history, medications, and care team. AI-enabled Notetaker: olivia can provide patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app's AI interface. Medical Image Sharing: olivia allows patients to easily upload, view, and share their DICOM images in a browser native platform - pixel - with their doctors. Direct Data Import: Aggregate health records by connecting directly to a patient's healthcare provider's institution to organize and manage health records in one convenient place, including clinical data, scans, slides, molecular tests, and more.공시 • Jan 15Tempus AI, Inc. Announces the National Launch of FDA-Approved xT CDx TestTempus AI Inc. announced the national launch of the company's FDA-approved, NNGS-based in vitro diagnostic device, xT CDx. Beginning January 15, 2025, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the reported gene panels available. xT CDx are a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients. xT CDx leverages a normal-matched approach, which is a method of parallel DNA sequencing of a solid tumor and normal patient sample that can lead to more accurate identification of cancer-driving somatic variants. All orders for tumor + normal match tests - traditionally run on the company's signature xT assay - will now be run as xT CDx with no changes to the current ordering workflow. Clinicians can enhance molecular insights by adding xR RNA sequencing, xF/xF+ liquid biopsy, immunohistochemistry tests such as HER2 and PD-L1, and algorithmic tests such as homologous recombination deficiency (HRD) and immune profile score (IPS), which promote a streamlined, one-stop experience, supporting patient care.공시 • Jan 14+ 1 more updateTempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical CareTempus AI Inc. introduced a suite of new, transformative capabilities available in Tempus One, the company's generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneously advancing research to bring new drugs to market. This latest iteration now applies Tempus' proprietary Large Language Model (LLM) Agent Infrastructure (Agent Builder), which adapts LLMs to work on unstructured, multimodal healthcare data to improve clinical care and research. Tempus is building and deploying a series of AI models on top of its library of real-world, multimodal data that enables both physicians to access the data needed to make the most informed treatment decisions for their patients, as well as researchers to more easily uncover rapid insights for the development of the next generation of precision oncology treatments. The latest iteration of Tempus One includes four new breakthrough generative AI-powered capabilities that leverage LLMs to derive insights from unstructured data. Patient Query: Identifying and enrolling patients into clinical trials continues to be one of healthcare's biggest challenges. Tempus offers a suite of tools that support providers and study sponsors to get the right patient on the right experimental treatment at the right time. As part of its clinical trial matching program, TIME, Tempus is now deploying an internal agent that allows the company to analyze providers' structured and unstructured data to create a queue of patients that may be eligible for a specific trial. This agent can tap into unstructured data, such as progress notes, pathology reports, and imaging scans, which are important to understanding if a patient may be eligible for a trial. Tempus then sends the provider a notification for each patient that may be a match for that trial. Patient Timeline: Every patient's journey is unique. Throughout their care, a cancer patient typically encompasses hundreds of different records that document diagnostic results, treatment plans, physician notes, scans, and more. This makes it very difficult for physicians to have a comprehensive view of each patient's journey. Tempus One offers a solution, which leverages generative AI to seamlessly weave together those documents and create a cohesive timeline for a specific patient. Using an LLM-based data science model, Tempus One turns digital health records into a structured timeline of clinical events, featuring diagnostic results, changes in treatment, and more. A separate agent is then applied to query structured data to answer explicit questions posed by a physician. Prior Authorization:Drafting and submitting prior authorization forms can require hours of administrative work for care teams, an arduous but necessary process to ensure that patients receive coverage for specific treatments throughout their care journey. Now, a new agent inside of Hub, Tempus' provider platform, helps clinicians gather pertinent guidelines, drug labels, payer policy, and other relevant patient information, and outputs support documents tailored to each patient's case for further use by their care team. These datasets can include physician progress notes or medical images like pathology slides, providing researchers access to data that is not typically available, but critical when investigating new targets and patient populations. In particular, this new functionality expands the ability to investigate adverse events and reported symptoms, an increasingly popular query for many Tempus biopharma research customers.공시 • Nov 05Tempus AI, Inc (NasdaqGS:TEM) agreed to acquire Ambry Genetics Corporation from REALM IDx, Inc. for $600 million.Tempus AI, Inc (NasdaqGS:TEM) agreed to acquire Ambry Genetics Corporation from REALM IDx, Inc. for $600 million on November 5, 2024. A cash consideration of $375 million will be paid by Tempus AI, Inc. The consideration consists of common equity of Tempus AI, Inc having a value of $225 million to be issued for common equity of Ambry Genetics Corporation. As part of consideration, $600 million is paid towards common equity of Ambry Genetics Corporation. The transaction will be financed through senior debt of $300 million. Morgan Stanley, J.P. Morgan, and Allen & Company LLC represented the company in security financing. For the period ending March 31, 2024, Ambry Genetics Corporation reported total revenue of $240 million, operating loss of $8 million and net loss of $19 million. As of March 31, 2024, Ambry Genetics Corporation reported total assets of $160 million and net liabilities of $101 million. The expected completion of the transaction in first quarter of 2025. Cowen Inc. acted as financial advisor for Tempus AI, Inc.이익 및 매출 성장 예측BMV:TEM * - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282,284-108129220912/31/20271,942-22915651712/31/20261,594-346-63-31173/31/20261,364-303-220-186N/A12/31/20251,272-245-245-218N/A9/30/20251,105-203-249-221N/A6/30/2025952-199-73-52N/A3/31/2025803-720-213-193N/A12/31/2024693-745-211-189N/A9/30/2024640-801-207-190N/A6/30/2024596-790-325-292N/A3/31/2024562-293-284-249N/A12/31/2023532-254-249-214N/A9/30/2023485-276-266-233N/A12/31/2022321-334-187-168N/A9/30/2022293-325-192-173N/A12/31/2021258-298-224-212N/A9/30/2021285-296-205-193N/A6/30/2021284-286-199-188N/A3/31/2021236-270-209-198N/A12/31/2020188-254-220-207N/A12/31/201962-148N/A-117N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: TEM * 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: TEM * 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: TEM * 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: TEM * 의 수익(연간 16.4%)이 MX 시장(연간 6.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: TEM * 의 수익(연간 16.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: TEM *의 자본 수익률은 3년 후 19.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 11:08종가2026/05/20 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Tempus AI, Inc.는 23명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Catherine Ramsey SchulteBairdMichael RyskinBofA Global ResearchMark MassaroBTIG20명의 분석가 더 보기
공시 • May 07Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2026Tempus AI, Inc. increased earnings guidance for the full year 2026. For the period, the company expects revenue in range of $1.59 billion to $1.60 billion, which represents ~25% annual growth.
Breakeven Date Change • Dec 31Forecast to breakeven in 2028The 14 analysts covering Tempus AI expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$17.7m in 2028. Average annual earnings growth of 44% is required to achieve expected profit on schedule.
공시 • Aug 08Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2025Tempus AI, Inc. increased earnings guidance for the full year 2025. For the period, the company now expects revenue of approximately $1.26 billion for the consolidated business, which represents approximately 82% annual growth.
공시 • May 07Tempus AI, Inc. Increases Earnings Guidance for Full Year 2025Tempus AI, Inc. increased earnings guidance for full year 2025. The company now expects full year revenue of approximately $1.25 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 80% annual growth.
공시 • Feb 25Tempus Ai, Inc. Provides Earnings Guidance for Full Year 2025Tempus AI, Inc. provided earnings guidance for full year 2025. Tempus now expects full year 2025 revenue of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth.
공시 • May 07Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2026Tempus AI, Inc. increased earnings guidance for the full year 2026. For the period, the company expects revenue in range of $1.59 billion to $1.60 billion, which represents ~25% annual growth.
Reported Earnings • May 06First quarter 2026 earnings released: US$0.70 loss per share (vs US$0.40 loss in 1Q 2025)First quarter 2026 results: US$0.70 loss per share (further deteriorated from US$0.40 loss in 1Q 2025). Revenue: US$348.1m (up 36% from 1Q 2025). Net loss: US$125.9m (loss widened 85% from 1Q 2025). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Global Life Sciences industry.
공시 • Apr 21Tempus AI, Inc. to Report Q1, 2026 Results on May 05, 2026Tempus AI, Inc. announced that they will report Q1, 2026 results on May 05, 2026
공시 • Apr 14Tempus AI, Inc. Launches Automated Active Follow-Up ServiceTempus AI, Inc. announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an active follow-up track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus’ secure, AI-enabled physician portal. Because NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient’s ongoing treatment journey. Tempus is addressing this challenge by automatically surfacing updated therapy recommendations when clinical guidelines change or new therapeutic options emerge—all without requiring a new patient sample. This ensures that patient insights remain as current as the science, supporting evidence-based decision-making throughout the patient’s treatment journey.
공시 • Apr 08Tempus AI, Inc., Annual General Meeting, May 21, 2026Tempus AI, Inc., Annual General Meeting, May 21, 2026.
공시 • Apr 01Tempus AI, Inc. Announces Results from ALERT TrialTempus AI, Inc. announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electronic clinician notifications (ECNs) integrated into the electronic health record (EHR) significantly improve the timely evaluation and treatment of patients with significant aortic stenosis (AS) and mitral regurgitation (MR). Valvular heart disease is a leading cause of morbidity and mortality, yet it remains frequently undertreated. For patients with untreated symptomatic severe AS, mortality approaches 50% within just two years. Similarly, untreated severe MR carries a median survival of only five years. The ALERT trial was designed to determine if automated, AI-driven alerts could bridge this critical gap in care delivery. By leveraging the Tempus Next platform, which applies natural language processing to accurately extract findings from echocardiogram reports, the trial enabled real-time detection of significant disease and automatically delivered notifications with site-specific guideline-based care notifications directly to providers. The ALERT trial included 765 clinicians and 2,016 echocardiograms across five U.S. health systems and 35 hospitals. The study met its primary endpoint, demonstrating that automated ECN alerts were superior to usual care in a win ratio analysis (win ratio 1.27; P = .007), meaning patients in the alert group were 27% more likely to be evaluated by the multidisciplinary heart team or receive a valve intervention than those in the usual care group. By delivering actionable data directly to providers, the system facilitated a 40% relative increase in life-saving valve procedures (13.4% vs. 9.6%) and a 27% increase in multidisciplinary heart team evaluations (22.7% vs. 17.9%) within just 90 days. These alerts effectively reduced clinical inertia, prompting earlier specialist referrals and ensuring patients received interventions within established benchmarks for timely care. Beyond clinical efficiency, a central objective of the ALERT trial was to confront the persistent disparities that leave women, older adults, racial and ethnic minorities, and rural residents at higher risk of being undertreated. These findings suggest that EHR-integrated clinical decision support can serve as a powerful, scalable 'safety net,' standardizing care delivery to help ensure high-risk findings receive timely action regardless of a patient's demographics or care setting. While the ALERT trial was conducted in collaboration with Medtronic, the automated clinician notifications were designed to be device-agnostic to promote standardized care delivery, without requiring providers to use specific Medtronic devices for recommended evaluations or interventions.
공시 • Mar 11Tempus Ai, Inc. Announces the Publication of A New Study in Jco Precision OncologyTempus AI, Inc. announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex identify actionable findings that are missed by more limited standard in-network testing. While organizations like ASCO and the NCCN strongly advocate for CGP to guide precision therapies, current guidelines often lack specificity regarding the exact composition or essential features required within these panels. This research demonstrates that CGP value extends far beyond simple panel size, highlighting the utility of advanced testing features to more fully capture clinically relevant findings. In the study, 12% (approximately 1 in 8) of patients across the pilot and expanded cohorts had potentially actionable findings associated with an approved therapy identified solely through advanced Tempus features—such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing—that would otherwise have been missed by less comprehensive tests.
Recent Insider Transactions • Feb 26Executive VP recently sold Mex$20m worth of stockOn the 20th of February, Andrew Polovin sold around 19k shares on-market at roughly Mex$1,026 per share. This transaction amounted to 58% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$353m more than they bought in the last 12 months.
Reported Earnings • Feb 25Full year 2025 earnings released: US$1.41 loss per share (vs US$6.23 loss in FY 2024)Full year 2025 results: US$1.41 loss per share (improved from US$6.23 loss in FY 2024). Revenue: US$1.27b (up 83% from FY 2024). Net loss: US$245.0m (loss narrowed 67% from FY 2024). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Global Life Sciences industry.
공시 • Feb 25+ 1 more updateTempus AI, Inc. (NasdaqGS:TEM) acquired Oneome LLC.Tempus AI, Inc. (NasdaqGS:TEM) acquired Oneome LLC in November 2025. Tempus AI, Inc. (NasdaqGS:TEM) completed the acquisition of Oneome LLC in November 2025.
공시 • Feb 18Tempus AI, Inc. Announces Novel Pan-Cancer HRD-RNA AlgorithmTempus AI, Inc. announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays. Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. Unlike traditional DNA tests that analyze static "genomic scars"--which may persist even after a patient develops drug resistance--this RNA-based approach provides a dynamic, real-time assessment of a tumor's functional status. By analyzing gene expression rather than structural DNA damage, the algorithm can detect HRD in patients and cancer types where genomic scarring is rare or difficult to identify. This advanced methodology allows the model to capture HRD status in patients who might be missed by DNA-based assays, significantly expanding the population that can be identified for potentially life-saving therapies. A real-world validation study demonstrates that HRD-RNA positive metastatic pancreatic patients treated with first line platinum-based regimens showed a significant reduction in mortality risk compared to those receiving non-platinum first line therapies. These findings, including the complete supporting data, will be published later this year. HRD-RNA is currently available for research use only in the detection of HRD status within solid tumor patient populations and for the identification of patients likely to respond to platinum regimens or PARP inhibitor therapy. Clinical availability is expected later this year.
공시 • Feb 10Tempus AI, Inc. to Report Q4, 2025 Results on Feb 24, 2026Tempus AI, Inc. announced that they will report Q4, 2025 results on Feb 24, 2026
공시 • Jan 27Tempus Ai, Inc. Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional BiomarkersTempus AI, Inc. announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), and PD-L1. IPS is a multimodal biomarker that combines known and novel clinical and immune-related biomarkers from DNA and RNA analysis to predict a patient's response to ICI-based therapy. The new clinical validation results demonstrate that IPS consistently outperforms conventional biomarkers, highlighting its potential to change the way physicians can identify patients most likely to benefit from immunotherapy. In four independent validation cohorts of pan-cancer metastatic solid organ cancer patients, IPS was shown to be a more accurate predictor of ICI outcomes (HR=0.45) than TMB, MSS, and PD-L1, demonstrating prognostic utility that is independent of those conventional biomarkers. IPS identified 13% of patients with microsatellite stable colorectal cancer who demonstrated strong real-world overall survival with ICI treatment (HR=0.2), indicating that ICI immunotherapy may be a viable option for a key patient population that might have been overlooked with conventional biomarkers alone. Beyond colorectal cancer, the study's findings highlight how IPS could expand treatment options for patients with rare cancers. IPS classified 17% of patients with rare metastatic solid tumors as "IPS-High," despite these patients not falling within a cancer-specific FDA-approved ICI label. The significant difference in median real-world overall survival in "IPS High" versus "IPS-Low" patients (HR=0.26) shows that ICI could be a relevant and potentially life-saving option for patients that might otherwise be missed. The test is available as an add-on for clinicians ordering Tempus' xT (DNA) and xR (RNA) assays, helping to manage patients on immunotherapy by utilizing data already collected as part of a patient's standard sequencing.
공시 • Jan 21Tempus AI, Inc. Announces the Launch of Paige PredictTempus AI, Inc. announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence or absence of clinically actionable and relevant biomarkers directly from a single H&E slide, offering physicians insights even when tissue samples are insufficient for full molecular profiling. As the demand for next-generation sequencing (NGS) and immunohistochemistry (IHC) testing grows, so does the challenge of limited tissue availability. When a sample is "quantity not sufficient" (QNS), patients can face delays of days or weeks for testing results, waiting for repeat biopsies or alternative testing, ultimately prolonged uncertainty and potentially impacting treatment options. Paige Predict's ability to use an H&E image to identify biomarkers that are more or less likely to be present in the specimen can be used by clinicians to inform the sequence in which they will order confirmatory tissue-based tests, maximizing the likelihood of receiving an actionable result before exhausting tissue. Leveraging Tempus and Paige's intelligent digital pathology platform and proprietary AI products, Paige Predict identifies critical biomarker information from even scarce amounts of tissue and analyzes H&E images to predict the likelihood of 123 biomarkers and oncogenic molecular pathways in 16 cancer types, including NSCLC, prostate, breast, pancreatic, colorectal, and more. Results are automatically delivered with the clinical report to ordering physicians. Paige Predict was built using Paige's foundation model and a combined, multimodal cohort from Tempus and Paige, which contains de-identified data on over 200,000 patients. The model has been rigorously validated to demonstrate performance, generalizability and robustness across multiple, diverse datasets, including a large-scale cohort from Tempus.
Breakeven Date Change • Dec 31Forecast to breakeven in 2028The 14 analysts covering Tempus AI expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$17.7m in 2028. Average annual earnings growth of 44% is required to achieve expected profit on schedule.
Recent Insider Transactions • Dec 14Independent Director recently sold Mex$5.2m worth of stockOn the 5th of December, Wayne Frederick sold around 4k shares on-market at roughly Mex$1,405 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth Mex$166m. Insiders have been net sellers, collectively disposing of Mex$5.4b more than they bought in the last 12 months.
Recent Insider Transactions • Dec 10Independent Director recently sold Mex$5.2m worth of stockOn the 5th of December, Wayne Frederick sold around 4k shares on-market at roughly Mex$1,405 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth Mex$166m. Insiders have been net sellers, collectively disposing of Mex$7.3b more than they bought in the last 12 months.
공시 • Dec 09Tempus AI, Inc. Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer SymposiumTempus AI, Inc. announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9-12 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Tempus will highlight its latest scientific and clinical research findings via ten poster presentations: Integrative Modeling of Multimodal Real-World Data for Improved Risk Stratification of First-Line CDK4/6 inhibitor plus endocrine treatment and identify predictors of response. This study demonstrated that multimodal real-world data collected during routine care can provide valuable insights into the biology of response to CDK4/6 inhibitors in patients with metastatic breast cancer and help improve patient stratification. Distinct Transcriptional and Immunosuppressive Microenvironment Signatures in PIK3CA-mutant Hormone Receptor Positive (HR+)/HER2- Metastatic Breast Cancer (MBC). Date/Time: December 10, 2025, 12:30 p.m. - 2:30 p.m. CDT. Presentation Number: PS1-11-08. Summary: This study compared transcriptomic and immune profiles in HR+/HER2- metastatic breast cancer across wild-type, PIK3CA-mutants, ESR1-mutant, and co-mutant groups. SFRP2 downregulation was specific to ESR1-mutant tumors, while SCGB2A2 was robustly upregulated in PIK3CA- mutant and co-mutant tumors, suggesting its potential as a diagnostic and therapeutic target. Immune analysis revealed increased M2 macrophages and regulatory T cells in PIK3CA- mutualant and co-mutant tumor, with the most pronounced immunosuppressive microenvironment in PIK3CA-Mutant cases. A notable percentage of patients with localized and de novo metastatic disease displayed TMB high status and/or PD-L1 positivity. Additionally, TMB-high and PD-L1 positive patients with de novo metastatic disease treated with first-line chemotherapy or anti-HER2 therapy had significantly worse real-world overall survival (rwOS), suggesting a potential therapeutic benefit of incorporating immunotherapy into the treatment paradigm, in both localized and metastatic disease settings. Furthermore, observed ethnic HLA polymorphisms in the cohort may contribute to differences in outcomes and could potentially guide the development of population-specific immunotherapeutic strategies. Real-World Data (RWD) Outcome Analysis of ESR1 Mutation Emergence in HR+/HER2 - Metastatic Breast Cancer through the Continuum of Standard of Care Hormonal Therapy. Date/Time: Friday, December 12, 2025, 12:30p.m. - 2:00 p.m. CDT, Presentation Number: PS5-05-02. Summary: This large multimodal RWD outcome analysis from longitudinal molecular surveillance testing (xF) in HR+/HER2. mBC patients treated with AI+CDK4/6 inhibitor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer. Date/Time: December 12, 2025, 12; 12:30 p.m., 2:00 p.m., CDT and Presentation Number: PS5.05-02; Summary: This large multimodAL RWD outcome analysis from longitudinal Molecular surveillance testing (xF)in HR+/HER2- mBC pts treated with AI+ CDK4/6 inhibitors treated with AI+CDK 4/6 inhibitor plus end endocrine treatment and resistance. These insights are essential for pinpointing patient populations who may benefit from novel therapies and for optimizing treatment strategies to ultimately improve outcomes for those with advanced disease.
Recent Insider Transactions • Nov 23Co-Founder recently sold Mex$166m worth of stockOn the 20th of November, Eric Lefkofsky sold around 130k shares on-market at roughly Mex$1,275 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Eric has been a net seller over the last 12 months, reducing personal holdings by Mex$4.4b.
New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$204m Forecast net loss in 3 years: US$18m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Significant insider selling over the past 3 months (Mex$103m sold).
Reported Earnings • Nov 06Third quarter 2025 earnings released: US$0.46 loss per share (vs US$0.46 loss in 3Q 2024)Third quarter 2025 results: US$0.46 loss per share. Revenue: US$334.2m (up 85% from 3Q 2024). Net loss: US$80.0m (loss widened 5.5% from 3Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Global Life Sciences industry.
공시 • Nov 05+ 1 more updateTempus AI, Inc. Announces Six Abstracts Accepted for Presentation At the Society for Immunotherapy of Cancer Annual Meeting 2025Tempus AI, Inc. announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. This year, Tempus will highlight its latest scientific and clinical research findings via six poster presentations. A novel multi-omic algorithm to predict real-world outcomes among patients with rare, advanced, solid cancers treated with off-label immune checkpoint inhibitors. Date/Time: November 7, 5:10-6:35 p.m. ET. Location: Exhibit Halls AB. Presentation Number: 157. This study investigates the utility of the Immune Profile Score (IPS) as a molecular signature to predict the effectiveness of immune checkpoint inhibitor (ICI) therapy in rare, advanced solid cancers. Given the clinical unmet need for rare, heterogeneous cancers, the study evaluated 90 eligible patients from Tempus' de-identified real-world database who had a rare, advanced solid cancer diagnosis and received off-label ICI treatment, excluding those with high TMB or MSI. Patients were further categorized as IPS-high or IPS-low. The findings demonstrated that IPS-high patients experienced significantly longer overall survival compared to those categorized as IPS-low. Importantly, IPS maintained its prognostic significance across all patient subgroups and clinically relevant confounders. These results support IPS as a pan-cancer biomarker capable of accurately stratifying ICI treatment outcomes and potentially supporting the label expansion of ICIs to various rare cancer types. Furthermore, a comparison of IPS risk stratification on ICI therapy versus prior non-ICI regimen provided additional insight about IPS's utility as an ICI-specific biomarker. This hypothesis-generating data address an unmet need for patients whom an ICI therapy and predictive biomarker are urgently needed. Ultrahigh tumor mutational burden (TMB) is associated with improved survival outcomes in patients (Pts) treated with immune checkpoint inhibitors (ICIs). Date/Time: Saturday, November 8, 2025; 5:10-6: 35 p.m. ET; Location: Exhibit Halls AB; Presentation Number: 136; Summary: This research evaluates the prognostic value of defining an "ultrahigh" tumor mutational burden (T MB) threshold (40 mutations/MB) compared to the standard 10 mt/MB cutoff for patients receiving immune checkpoint inhibitor (ICI") therapy. Using Tempus Lens, the research team defined a cohort of 17,449 patients with five different cancer types (melanoma, lung, GI, non-melanoma skin, and uterine) from Tempus' de- identified multimodal database. The analysis sought to compare real-world objective response rates (rwORR) and overall survival (rwOS) across low, high, and ultrahigh TMB groups. The findings indicate that patients in the ultrahigh TMB group experience significantly improved clinical outcomes, including enhanced rwORR and better rwOS. This ultrahigh TMB status is also linked to a distinct tumor microenvironment, specifically showing a higher degree of regulatory T cell and myeloid cell infiltration, suggesting that ultrahigh TMB may serve as a novel marker for predicting ICI responsiveness. Impact of androgen receptor mutations on immune infiltration in castration resistant prostate cancer. Date/Time: Saturday, Nov. 8; 5:10-6-6:35 p. m. ET; Location: Exhibit Hall AB; Presentation Number: 140; Summary: A detailed analysis using Tempus' de-identified Real-world database examined the relationship between androgen receptor (AR) alterations and the immune microenvironment in 1,556 patients with off-label immune micro environment in 1,556 patients with the immune micro environment in 1,58 patients with the immune microenvironment.
공시 • Oct 21Tempus AI, Inc. to Report Q3, 2025 Results on Nov 04, 2025Tempus AI, Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025
공시 • Sep 23Tempus AI, Inc. Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS in Vitro Diagnostic DeviceTempus AI, Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life science tool to support drug development programs. RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases, including enhanced fusion detection. RNA analysis is increasingly an important tool in research and development because it can identify molecular pathways and networks that are directly involved in disease progression. The Tempus xR IVD assay is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of rearrangements in two genes, using RNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens from patients with solid malignant neoplasms. Information provided by xR IVD is intended to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed malignant neoplasms. Results from xR IVD are not intended to be prescriptive or conclusive for labeled use of any specific therapeutic product. The FDA authorization further solidifies Tempus as a one-stop-shop for precision medicine solutions. Collaborators can leverage Tempus' comprehensive collection of intelligent diagnostics and growing multimodal data that supports therapeutic innovation. xR IVD is one of the many solutions Tempus is applying to advance oncology therapeutic research and development.
공시 • Sep 11Tempus AI, Inc. Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel DeviceTempus AI, Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device's capabilities for cardiac MR image analysis. Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization. AI-enabled radiology, like Tempus Pixel, enhances medical imaging by rapidly analyzing scans, highlighting subtle abnormalities, and generating consistent, actionable insights. By improving accuracy and efficiency, it empowers clinicians to make faster, more informed decisions and deliver personalized patient care. Unlike conventional MR images that show only brightness differences, T1 and T2 maps provide precise numerical values to cardiac tissue characteristics, helping clinicians detect conditions such as fibrosis, inflammation, or edema, that may otherwise go undetected. With its newly cleared functionality, Tempus Pixel can now generate T1 and T2 inline map directly from raw MRI data, even when the scanner itself does not produce them, calculating values at every pixel across the image to create detailed DICOM maps for comprehensive tissue assessment. Tempus has developed and deployed a suite of advanced algorithms across radiology and pathology, helping physicians deliver more precision, personalized care. Its strategic acquisitions have further strengthened its footprint in these fields. In 2022, Tempus acquired Arterys, incorporating its AI-powered tools for analyzing imaging data--ranging from lung CT scans and chest X-rays to cardiac MRIs-- into Tempus' platform. Most recently, Tempus acquired Paige, an AI company specializing in digital pathology, bringing a proprietary dataset of almost 7 million clinically annotated, de-identified pathology slides to accelerate Tempus' efforts.
공시 • Sep 09Tempus AI, Inc. Announces New Study in JCO Precision Oncology Validating PurIST Algorithm for Enhanced Therapy Selection in Pancreatic CancerTempus AI, Inc. announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company's PurIST®? algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of PurIST into routine clinical care for patients with advanced PDAC, with the aim of informing first-line chemotherapy selection and improving patient outcomes. Pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and a five-year survival rate of just 12%. For patients with advanced, unresectable PDAC, the two most common first-line chemotherapy regimens, FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP), have shown variable efficacy, and clinicians have lacked robust biomarkers to guide optimal therapy selection. To address this challenge, Tempus collaborated with GeneCentric to develop and deploy PurIST, a clinically validated, RNA-based algorithm test that classifies PDAC tumors as either "classical" or "basal" subtypes. The Tempus-led study analyzed a real-world cohort of 931 patients with advanced PDAC, using the Tempus xR RNA sequencing platform to assign PurIST subtypes. Patients were treated with either first-line FFX or GnP, and clinical outcomes were assessed according to PurIST classification. The study's findings establish PurIST as both a prognostic and predictive biomarker, enabling clinicians to personalize first-line therapy for advanced PDAC patients and maximize the likelihood of improved survival. Prognostic Value: Among patients treated with FFX (N=536), those with the classical subtype had a significantly longer median overall survival (OS) of 11.8 months, compared to 7.0 months for basal subtype patients (Hazard Ratio [HR]=1.86; p; Predictive Value: In patients with the classical subtype and good performance status (ECOG 0 or 1, N=311), treatment with FFX was associated with a 33% relative risk reduction in death compared to GnP (HR=0.67; p<0.009). No comparable benefit was observed in basal subtype patients.
Recent Insider Transactions • Aug 30Independent Director recently sold Mex$28m worth of stockOn the 26th of August, Theodore Leonsis sold around 20k shares on-market at roughly Mex$1,418 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth Mex$57m. Insiders have been net sellers, collectively disposing of Mex$7.1b more than they bought in the last 12 months.
공시 • Aug 23Tempus AI, Inc. (NasdaqGS:TEM) acquired Paige.AI, Inc. in a transaction valued at $81.2 million.Tempus AI, Inc. (NasdaqGS:TEM) acquired Paige.AI, Inc. in a transaction valued at $81.2 million on August 22, 2025. The consideration consists of $81.25 million, which is being paid predominantly in Tempus common stock, as well as Tempus’ assumption of Paige’s remaining commitment under its existing Microsoft Azure cloud services agreement. Morgan Stanley (NYSE:MS) acted as financial advisor to Paige.AI, Inc. Tempus AI, Inc. (NasdaqGS:TEM) completed the acquisition of Paige.AI, Inc. on August 22, 2025.
Recent Insider Transactions • Aug 17Independent Director recently sold Mex$57m worth of stockOn the 13th of August, Theodore Leonsis sold around 44k shares on-market at roughly Mex$1,302 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$7.0b more than they bought in the last 12 months.
Reported Earnings • Aug 10Second quarter 2025 earnings released: US$0.25 loss per share (vs US$6.86 loss in 2Q 2024)Second quarter 2025 results: US$0.25 loss per share (improved from US$6.86 loss in 2Q 2024). Revenue: US$314.6m (up 90% from 2Q 2024). Net loss: US$42.8m (loss narrowed 92% from 2Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry.
공시 • Aug 09Tempus AI, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.Tempus AI, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Class A Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Aug 08Tempus AI, Inc. Increases Earnings Guidance for the Full Year 2025Tempus AI, Inc. increased earnings guidance for the full year 2025. For the period, the company now expects revenue of approximately $1.26 billion for the consolidated business, which represents approximately 82% annual growth.
공시 • Aug 02Bragar Eagel & Squire, P.C. Files A Class Action Lawsuit Against Tempus Ai, IncBragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of "round-tripping" capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable "pass-through payment" via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025.
공시 • Jul 22Tempus AI, Inc. to Report Q2, 2025 Results on Aug 08, 2025Tempus AI, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025
공시 • Jun 03+ 1 more updateTempus AI, Inc. Introduces xM, an Assay to Monitor Immunotherapy Response for Patients with Advanced CancersTempus AI, Inc. announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It is currently available for research use only, with clinical availability expected later this year. In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding estimated response rate of 20.13%.1 xM for TRM is designed to quantify changes in circulating tumor DNA (ctDNA) longitudinally from a blood sample, enabling early molecular response assessment in patients with advanced cancers receiving immunocheckpoint inhibitors (ICI) alone or combination therapies. xM for TRM leverages a unique multi-parametric algorithm, integrating copy number variations (CNVs), along with somatic andgerline variant allele frequencies (VAFs), for a comprehensive and robust estimation of circulating tumor fraction. Tempus is presenting new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®?) Annual Meeting, highlighting the assay's potential to help clinicians monitor response and refine treatment strategies for patients with advanced cancers. Title: A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors. Date/Time: June 2, 2025; 1:30 PM-4:30 PM CDT; Location: Poster Section Developmental Therapeutics--Immunotherapy (Poster #205). Overview: Tempus xM for TRM, a liquid biopsy test, monitors treatment response by tracking ctDNA dynamics over time. Longitudinal non-molecular responders are associated with worse survival compared to molecular responders, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions.
공시 • Jun 01Tempus Ai, Inc. Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using Its Novel Foundation ModelTempus AI, Inc. announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality. Over the past decade, Tempus has built a multimodal data library of over 40 million research records, including more than 1.5 million records with matched clinical data linked with genomic information, 2 million records with imaging data, and approximately 300,000 records with genomic and whole transcriptomic data. The scale and size of this data library will allow the company to uncover groundbreaking discoveries that were previously out of reach. Fuses will accelerate Tempus' comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. Insights from Fuses will be developed into clinically validated algorithmic diagnostics that may enable highly personalized care, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. Tempus has already begun this work with last year's launch of its Immune Profile Score (IPS) a multimodal biomarker that can be used as a prognostic indicator for adult patients with metastatic pan-solid tumors eligible for immune checkpoint inhibitor (ICI)-based therapy. The foundational model behind Fuses is learning generalizable rules determining prognosis and drug benefit in real-world practice. With the goal of furthering researchers' understanding of why certain clinical trials fail, identify new indications for investigational drugs, optimize trial design, and uncover combination therapies to broaden patient benefit. By revealing biomarker rules, the model may also surface mechanisms of drug response and resistance to inspire a new generation of companion diagnostics and therapeutic research.
Recent Insider Transactions • May 24Co-Founder recently sold Mex$20m worth of stockOn the 20th of May, Eric Lefkofsky sold around 17k shares on-market at roughly Mex$1,218 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth Mex$1.7b. Eric has been a net seller over the last 12 months, reducing personal holdings by Mex$4.2b.
Board Change • May 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Director Jennifer Doudna was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 07First quarter 2025 earnings released: US$0.40 loss per share (vs US$1.47 loss in 1Q 2024)First quarter 2025 results: US$0.40 loss per share (improved from US$1.47 loss in 1Q 2024). Revenue: US$255.7m (up 75% from 1Q 2024). Net loss: US$68.0m (loss narrowed 27% from 1Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Global Life Sciences industry.
공시 • May 07Tempus AI, Inc. Increases Earnings Guidance for Full Year 2025Tempus AI, Inc. increased earnings guidance for full year 2025. The company now expects full year revenue of approximately $1.25 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 80% annual growth.
공시 • May 06Tempus Ai, Inc. Announces Notetaker, Its Ai-Powered Clinical Assistant for PsychiatryTempus AI, Inc. has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, aggressively records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records. Notetaker complements Tempus' existing mental health platform designed to support clinicians in delivering personalized care. It joins other precision medicine solutions, including the Tempus nP pharmacogenomic test and PRO, the company's patient reported outcome solution. Key features of Notetaker include: Recording Sessions: Notetaker effortlessly transcribes and processes the session in real-time, capturing key details with precision, including specialized psychiatric terminology and medications. Generating Notes: At the end of each session, a clinical note is automatically created, highlighting essential information such as symptoms, progress, and action plans for quick review. Refining During Review: Clinicians can easily review and modify the autogenerated note using the Magic Edit features to adjust formatting or details according to their preferences. Care Gap Notification: Notetaker identifies and helps close care gaps with real-time pharmacogenomic insights for medications under consideration. Notetaker is capable of understanding more than 30 languages, including English, Spanish, and Chinese. It can seamlessly recognize language switching without the need to set a specific language in advance. With adjustable settings tailored for telehealth, in-person sessions, and dictation, Notetaker adapts to various environments for adequate audio capture. While providers are responsible for obtaining all necessary consents before recording sessions, Notetaker supports HIPAA-compliant data transfer and storage.
공시 • May 01Tempus AI, Inc. Time Network Expands Support of Phase I Clinical Trials to Accelerate Activation and EnrollmentTempus AI, Inc. is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform with a focus on activating and enrolling quickly across over 40 phase I-capable research centers. Most recently, TIME enrolled the First Patient In (FPI) for multiple phase I trials. The TIME Network is powered to efficiently enroll patients within its participating data-integrated site base, in which patients are identified and matched to trials and sites are activated within days or weeks. At the Taylor Cancer Research Center (TCRC), Tempus activated the site in approximately two weeks for the Nimbus 9216-101 study, and enrolled its first patient within one month of site activation. For the Pathos P300-02-001 study, Tempus screened and enrolled the trial's first and second patients at Nebraska Cancer Specialists and Oncology Consultants within weeks.
공시 • Apr 28Tempus AI, Inc. Introduces Loop, an AI-Powered Target Discovery and Validation PlatformTempus AI, Inc. announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic development. One of the biggest industry challenges has been translating promising preclinical experiments into treatments that can benefit patients. Conventional approaches in target discovery and validation rely on cell lines or animal models, which may not be reliable representations of human tumors. Loop's approach is uniquely powerful because it leverages Tempus' rich RWD to identify patient subpopulations with similar clinical, pathologic, and molecular patterns, followed by use of systems biological approaches to help reveal novel target genes and multimodal signatures. These signatures allow Tempus to seamlessly map patient subcohorts to relevant patient-derived organoids (PDOs), which the company has been expanding for years. By ensuring continuity between RWD and PDOs, Tempus can validate targets using high-throughput functional screens in models that more closely reflect patient attributes. This seamless integration--RWD to PDO and back--can help to enable rapidhesis generation and testing in the most relevant disease models, accelerating target discovery and validation. Tempus has already deployed its Loop platform to prioritize drug targets in patient subpopulations with severe unmet needs for a large pharmaceutical company. By incorporating a lab-in-the-loop strategy, its biological modeling and functional screening capabilities were able to confirm and validate these targets within a year, a significant acceleration of the standard discovery timeline.
공시 • Apr 24Tempus AI, Inc. to Report Q1, 2025 Results on May 06, 2025Tempus AI, Inc. announced that they will report Q1, 2025 results on May 06, 2025
공시 • Apr 01Tempus AI, Inc., Annual General Meeting, May 20, 2025Tempus AI, Inc., Annual General Meeting, May 20, 2025.
공시 • Mar 12Tempus AI, Inc. (NasdaqGS:TEM) acquired Deep 6 AI Inc.Tempus AI, Inc. (NasdaqGS:TEM) acquired Deep 6 AI Inc. on March 11, 2025. Tempus AI, Inc. (NasdaqGS:TEM) completed the acquisition of Deep 6 AI Inc. on March 11, 2025.
공시 • Feb 25Tempus Ai, Inc. Provides Earnings Guidance for Full Year 2025Tempus AI, Inc. provided earnings guidance for full year 2025. Tempus now expects full year 2025 revenue of approximately $1.24 billion for the consolidated Tempus and Ambry Genetics business, which represents approximately 79% annual growth.
Reported Earnings • Feb 25Full year 2024 earnings released: US$6.23 loss per share (vs US$4.20 loss in FY 2023)Full year 2024 results: US$6.23 loss per share (further deteriorated from US$4.20 loss in FY 2023). Revenue: US$693.4m (up 30% from FY 2023). Net loss: US$746.3m (loss widened 181% from FY 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry.
공시 • Feb 11Tempus AI, Inc. to Report Q4, 2024 Results on Feb 24, 2025Tempus AI, Inc. announced that they will report Q4, 2024 results on Feb 24, 2025
공시 • Feb 04Tempus AI, Inc (NasdaqGS:TEM) completed the acquisition of Ambry Genetics Corporation from REALM IDx, Inc.Tempus AI, Inc (NasdaqGS:TEM) agreed to acquire Ambry Genetics Corporation from REALM IDx, Inc. for approximately $600 million on November 4, 2024. Pursuant to the terms of the Purchase Agreement, consideration for the Acquisition consists of $375 million in cash, subject to adjustment for cash, unpaid indebtedness, unpaid transaction expenses and net working capital of Ambry, plus the issuance of an aggregate of 4,843,136 shares of the Tempus AI, Inc’s Class A common stock. In connection with the Purchase Agreement, Tempus AI, Inc entered into a debt commitment letter, dated November 4, 2024, with affiliates of Ares Capital Corporation, pursuant to which Ares has committed to provide (i) a $100 million senior secured revolving credit facility and (ii) additional term loans in an aggregate principal amount of $200 million. The Company expects to utilize borrowings under the Additional Term Loan and the Revolving Credit Facility to fund the Cash Consideration for the Acquisition and to pay fees and expenses related thereto. The consummation of the Acquisition is subject to certain specified closing conditions set forth in the Purchase Agreement, including the receipt of certain regulatory approvals. Subject to the terms of the Purchase Agreement, Tempus AI, Inc is required to use reasonable best efforts to obtain the approval required pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. For the period ending March 31, 2024, Ambry Genetics Corporation reported total revenue of $240 million, operating loss of $8 million, reported total assets of $160 million and Consolidated net assets of $101 million. The expected completion of the transaction in first quarter of 2025. Cowen Inc. acted as financial advisor for Tempus AI, Inc. Richard Ginsberg and Erin Kirchner of Cooley LLP acted as legal advisor to Tempus AI, Inc. Andrew L. Bab of Debevoise & Plimpton LLP and Yasuhiro Kasahara of Nagashima Ohno & Tsunematsu acted as legal advisors to REALM IDx, Inc. TD Securities Inc. acted as a financial advisor to Tempus AI, Inc. Mitsubishi UFJ Morgan Stanley Securities acted as the financial advisor to Konica Minolta. Tempus AI, Inc (NasdaqGS:TEM) completed the acquisition of Ambry Genetics Corporation from REALM IDx, Inc. on February 03, 2025.
Recent Insider Transactions • Jan 26Co-Founder recently sold Mex$1.3b worth of stockOn the 24th of January, Eric Lefkofsky sold around 1m shares on-market at roughly Mex$1,039 per share. This transaction amounted to 3.5% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth Mex$1.6b. This was Eric's only on-market trade for the last 12 months.
공시 • Jan 21Tempus AI, Inc. Announces National Launch of olivia, its AI-Enabled Personal Health Concierge App for PatientsTempus AI Inc. announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. olivia is designed to address two core objectives - centralizing patients' health data and making that data accessible and actionable through AI. The app enables patients to bring their health information into one unified platform. Patients can connect directly to over 1,000 health systems through electronic health record (EHR) integration, sync data from health devices to track daily metrics, or manually upload health records. olivia then organizes that data into a dynamic timeline where patients can access their records, including lab results, imaging reports, visit summaries, and even deep clinical data such as DICOM images, which can be shared directly with a patient's care team. olivia's AI-enabled capabilities allow patients to ask questions about their records, summarize their health information, and receive responses informed by their data; for instance, patients can query, "summarize my health status," and olivia will provide a clear, concise summary of information in health data. Additionally, olivia connects to external resources, such as clinicaltrials.gov, to supplement the personalized insights offered from existing health data. A few, new features of olivia include: Smart Profile Summary: olivia synthesizes a patient's data - from both their provider and their manual profiles - into an AI-generated smart profile, detailing information such as their clinical diagnoses, family history, medications, and care team. AI-enabled Notetaker: olivia can provide patients with written transcripts, audio files, and smart summaries of physician appointments, accessible and searchable via the app's AI interface. Medical Image Sharing: olivia allows patients to easily upload, view, and share their DICOM images in a browser native platform - pixel - with their doctors. Direct Data Import: Aggregate health records by connecting directly to a patient's healthcare provider's institution to organize and manage health records in one convenient place, including clinical data, scans, slides, molecular tests, and more.
공시 • Jan 15Tempus AI, Inc. Announces the National Launch of FDA-Approved xT CDx TestTempus AI Inc. announced the national launch of the company's FDA-approved, NNGS-based in vitro diagnostic device, xT CDx. Beginning January 15, 2025, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the reported gene panels available. xT CDx are a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients. xT CDx leverages a normal-matched approach, which is a method of parallel DNA sequencing of a solid tumor and normal patient sample that can lead to more accurate identification of cancer-driving somatic variants. All orders for tumor + normal match tests - traditionally run on the company's signature xT assay - will now be run as xT CDx with no changes to the current ordering workflow. Clinicians can enhance molecular insights by adding xR RNA sequencing, xF/xF+ liquid biopsy, immunohistochemistry tests such as HER2 and PD-L1, and algorithmic tests such as homologous recombination deficiency (HRD) and immune profile score (IPS), which promote a streamlined, one-stop experience, supporting patient care.
공시 • Jan 14+ 1 more updateTempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical CareTempus AI Inc. introduced a suite of new, transformative capabilities available in Tempus One, the company's generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneously advancing research to bring new drugs to market. This latest iteration now applies Tempus' proprietary Large Language Model (LLM) Agent Infrastructure (Agent Builder), which adapts LLMs to work on unstructured, multimodal healthcare data to improve clinical care and research. Tempus is building and deploying a series of AI models on top of its library of real-world, multimodal data that enables both physicians to access the data needed to make the most informed treatment decisions for their patients, as well as researchers to more easily uncover rapid insights for the development of the next generation of precision oncology treatments. The latest iteration of Tempus One includes four new breakthrough generative AI-powered capabilities that leverage LLMs to derive insights from unstructured data. Patient Query: Identifying and enrolling patients into clinical trials continues to be one of healthcare's biggest challenges. Tempus offers a suite of tools that support providers and study sponsors to get the right patient on the right experimental treatment at the right time. As part of its clinical trial matching program, TIME, Tempus is now deploying an internal agent that allows the company to analyze providers' structured and unstructured data to create a queue of patients that may be eligible for a specific trial. This agent can tap into unstructured data, such as progress notes, pathology reports, and imaging scans, which are important to understanding if a patient may be eligible for a trial. Tempus then sends the provider a notification for each patient that may be a match for that trial. Patient Timeline: Every patient's journey is unique. Throughout their care, a cancer patient typically encompasses hundreds of different records that document diagnostic results, treatment plans, physician notes, scans, and more. This makes it very difficult for physicians to have a comprehensive view of each patient's journey. Tempus One offers a solution, which leverages generative AI to seamlessly weave together those documents and create a cohesive timeline for a specific patient. Using an LLM-based data science model, Tempus One turns digital health records into a structured timeline of clinical events, featuring diagnostic results, changes in treatment, and more. A separate agent is then applied to query structured data to answer explicit questions posed by a physician. Prior Authorization:Drafting and submitting prior authorization forms can require hours of administrative work for care teams, an arduous but necessary process to ensure that patients receive coverage for specific treatments throughout their care journey. Now, a new agent inside of Hub, Tempus' provider platform, helps clinicians gather pertinent guidelines, drug labels, payer policy, and other relevant patient information, and outputs support documents tailored to each patient's case for further use by their care team. These datasets can include physician progress notes or medical images like pathology slides, providing researchers access to data that is not typically available, but critical when investigating new targets and patient populations. In particular, this new functionality expands the ability to investigate adverse events and reported symptoms, an increasingly popular query for many Tempus biopharma research customers.
공시 • Nov 05Tempus AI, Inc (NasdaqGS:TEM) agreed to acquire Ambry Genetics Corporation from REALM IDx, Inc. for $600 million.Tempus AI, Inc (NasdaqGS:TEM) agreed to acquire Ambry Genetics Corporation from REALM IDx, Inc. for $600 million on November 5, 2024. A cash consideration of $375 million will be paid by Tempus AI, Inc. The consideration consists of common equity of Tempus AI, Inc having a value of $225 million to be issued for common equity of Ambry Genetics Corporation. As part of consideration, $600 million is paid towards common equity of Ambry Genetics Corporation. The transaction will be financed through senior debt of $300 million. Morgan Stanley, J.P. Morgan, and Allen & Company LLC represented the company in security financing. For the period ending March 31, 2024, Ambry Genetics Corporation reported total revenue of $240 million, operating loss of $8 million and net loss of $19 million. As of March 31, 2024, Ambry Genetics Corporation reported total assets of $160 million and net liabilities of $101 million. The expected completion of the transaction in first quarter of 2025. Cowen Inc. acted as financial advisor for Tempus AI, Inc.